代汉仁，教授

研究方向：细胞免疫治疗

联系电话：18311058779

电子邮箱：daihanren@ahmu.edu.cn

教育经历：

(1) 2017/09–2020/06，南京大学，药学，博士

(2) 2012/09–2015/06，解放军医学院,生物化学与分子生物学,硕士

(3) 2005/09–2009/07，蚌埠医学院,生物科学,学士

工作经历：

(1) 2024/01至今，维多利亚老品牌vic3308，维多利亚老品牌vic3308，教授

(2) 2020/10-2023/10，维多利亚老品牌vic3308第一附属医院，博士后

(3) 2009/09-2017/06，中国人民解放军总医院，基础医学研究所

科研项目：

（1）国家自然科学基金，面上项目，82470656，靶向活化肝星状细胞的FAP-CAR-T细胞治疗肝纤维化，2025/01-2028/12，46万元，在研，主持

（2）安徽省教育厅，CART细胞治疗器官纤维化，安徽省高校科研计划优秀青年项目，2024AH030023，2025/01-2027/12，50万元，主持

（3）国家自然科学基金，面上项目，82270641，CAR修饰巨噬细胞靶向杀伤肝星状细胞治疗肝纤维化，2023/01-2026/12，52万元，在研，主持

（4）国家自然科学基金，青年基金项目，81602711，双靶向CD19/CD22嵌合抗原受体治疗急性B淋巴细胞白血病的应用基础研究，2017/01-2019/12，17万元，结题，主持

（5）中国博士后科学基金第69批面上资助二等，2021M690186, 8万，结题，主持

发表论文情况：

1.Dai H†, Zhu C†, Huai Q, Xu W, Zhu J, Zhang X, Zhang X, Sun B, Xu H, Zheng M, Li X*, Wang H*. Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models. Journal of Hepatology. 2024 Feb 8:S0168-8278(24)00113-2.  (IF=26.8，ESI高被引论文)

2.Li X, Huai Q, Zhu C, Zhang X, Xu W,Dai H*, Wang H*. GDF15 ameliorates liver fibrosis by metabolic reprogramming of macrophages to acquire anti-inflammatory properties.Cellular and Molecular Gastroenterology and Hepatology.2023;16(5):711-734.(IF=7.2)

3.Li X†,Dai H†, Wang Y†, Wu Z†, Wang H, Qian W, Liang A, Han W. Regional empowerment through decentralised governance under a centralised regulatory system facilitates the development of cellular therapy in China.Lancet Haematol. 2022 Dec;9(12):e942-e954. (IF=24.7)

4.Wang Y†, Tong C†,Dai H†, Wu Z†, Han X†, Guo Y, Chen D, Wei J, Ti D, Liu Z, Mei Q, Li X, Dong L, Nie J, Zhang Y, Han W. Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming.Nat Commun.2021 Jan 18;12(1):409. (IF=17.694)

5.Dai H, Tong C, Shi D, Chen M, Guo Y, Chen D, Han X, Wang H, Wang Y, Shen P. Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial. Oncoimmunology. 2020 Nov 25;9(1):1846926.(IF=8.11)

6.Dai H†, Wu Z†, Jia H†, Tong C, Guo Y, Ti D, Han X, Liu Y, Zhang W, Wang C, Zhang Y, Chen M, Yang Q, Wang Y, Han W. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol. 2020 Apr 3;13(1):30. (IF=23.168，ESI高被引论文)

7.Dai H, Zhou Y, Tong C, Guo Y, Shi F, Wang Y*, and Shen P*.Restoration of CD3+CD56+ cell level improves skin lesions in severe psoriasis: A pilot clinical study of adoptive immunotherapy for patients with psoriasis using autologous cytokine-induced killer cells. Cytotherapy. 2018 Sep;20(9):1155-1163(IF=6.196)

8.Zhang Y†, Zhang W†,Dai H†, Wang Y, Shi F, Wang C, Guo Y, Liu Y, Chen M, Feng K, Zhang Y, Liu C, Yang Q, Li S, Han W*. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells. Sci China Life Sci. 2016 Apr;59(4):379-85.(IF=10.372)

9.Feng K†, Guo Y†,Dai H†, Wang Y, Li X, Jia H, Han W*. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer.Sci China Life Sci. 2016 May;59(5):468-79.(IF=10.372)

10.Dai H†, Zhang W†, Li X†, Han Q†, Guo Y, Zhang Y, Wang Y, Wang C, Shi F, Zhang Y, Chen M, Feng K, Wang Q, Zhu H, Fu X, Li S*, Han W*.  Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. Oncoimmunology. 2015; 4(11): e1027469.(IF=8.11)

11.Wang Y†, Bo J†,Dai HR†, Lu XC, Lv HY, Yang B, Wang T, Han WD*. CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo.Exp Hematol. 2013 Mar;41(3):241-52.e3.(IF=3.249)

12.Wang Y†,Dai H†, Li H†, Lv H, Wang T, Fu X*, Han W*. Growth of human colorectal cancer SW1116 cells is inhibited by cytokine-induced killer cells. Clin Dev Immunol. 2011;2011:621414. (IF=4.493)

13.Dai H†, Wang Y†, Lu X, Han W*. Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy. J Natl Cancer Inst. 2016 Jan 27;108(7).(IF=12.583)